Harvard Bioscience (HBIO) Plunges 84% – Will New CEO & Nasdaq Lifeline Spark a Turnaround?

Harvard Bioscience’s share price has been on a wild ride in 2025, mostly downhill. The stock now hovers around 40 cents, down from the mid-$2 range a year agofintel.io. In fact, HBIO has lost nearly 84% of its value year-over-yearfintel.io, an astonishing collapse that reflects both company-specific struggles and the broader market rout in small-cap biotech names. Shares cratered to an intraday low of $0.28 in mid-2025 amid intense selling pressureinvesting.com, before staging a modest rebound. Even after some recovery, HBIO remains deep in penny stock territory, a far cry from its 52-week high of $3.27investing.com.